膜聯(lián)蛋白A2(ANXA2)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)
CLIA Kit for Annexin A2 (ANXA2)
ANX-A2; ANX2L4; CAL1H; LIP2; LPC2; LPC2D; P36; PAP-IV; Protein I; Chromobindin-8; Calpactin-1 heavy chain; Lipocortin II; Placental anticoagulant protein IV
- 編號(hào)SCB944Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長2h, 40min
- 檢測(cè)范圍54.9-40,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于21.7pg/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3528 ¥ 5040 ¥ 22680 ¥ 42840 ¥ 352800
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)膜聯(lián)蛋白A2(ANXA2),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的膜聯(lián)蛋白A2(ANXA2)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 79-97 | 89 |
EDTA plasma(n=5) | 82-104 | 95 |
heparin plasma(n=5) | 93-101 | 96 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的膜聯(lián)蛋白A2(ANXA2),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中膜聯(lián)蛋白A2(ANXA2)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 82-103% | 87-95% | 91-99% | 78-101% |
EDTA plasma(n=5) | 79-99% | 81-101% | 86-104% | 80-99% |
heparin plasma(n=5) | 90-98% | 97-104% | 88-101% | 98-105% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測(cè)溶液A100μL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加底物100µL,37°C孵育10分鐘;
8. 讀數(shù)。
實(shí)驗(yàn)原理
將膜聯(lián)蛋白A2(ANXA2)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的膜聯(lián)蛋白A2(ANXA2)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的膜聯(lián)蛋白A2(ANXA2)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號(hào)。發(fā)射光強(qiáng)度和樣品中的膜聯(lián)蛋白A2(ANXA2)呈正相關(guān)。用化學(xué)發(fā)光儀測(cè)定相對(duì)光單位(RLU),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB944Hu03 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB944Hu01 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB944Hu04 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB944Hu01 | 膜聯(lián)蛋白A2(ANXA2)活性蛋白 | Cell?culture;?Activity?Assays. |
RPB944Hu02 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB944Hu01 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB; IHC; ICC; IP. |
PAB944Hu02 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB; IHC; ICC; IP; FCM |
LAB944Hu71 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAB944Hu22 | 膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | WB; IHC; ICC; IP. |
MAB944Hu21 | 膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | WB; IHC; ICC; IP. |
FAB944Hu08 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | Flow cytometry. |
FAB944Hu06 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | Flow cytometry. |
FAB944Hu04 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | Flow cytometry. |
FAB944Hu02 | 抗膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | Flow cytometry. |
SEB944Hu | 膜聯(lián)蛋白A2(ANXA2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCB944Hu | 膜聯(lián)蛋白A2(ANXA2)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMB944Hu | 膜聯(lián)蛋白A2(ANXA2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Journal of Cellular Biochemistry | Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis [PubMed: 20225235] |
World Journal of Gastroenterology | Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma [PubMed: PMC3491596] |
Oncology Letters | Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis [PubMed: PMC3742823] |
Ibrahim | Annexin A2 Versus Afp as An Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma [Ghrnet: Source] |
European Journal of Clinical Microbiology & Infectious Diseases | Serum annexin A2 levels in acute brucellosis and brucellar spondylodiscitis [Pubmed:24853056] |
Biomedicine & Pharmacotherapy | Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables [Pubmed:25661364] |
Hepat Mon | Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B [PubMed: 26587036] |
Tumour Biol | Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma [PubMed: 26109000] |
Biomed Pharmacother | Circulating [PubMed: 25661364] |
Tumour Biol | Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma [PubMed: 26189841] |
Eur J Clin Invest | Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population [PubMed: 26081791] |
Journal of Oral and Maxillofacial Surgery | Serum?Annexin?A2?Level?Is?Associated?With?Diagnosis?and?Prognosis?in?Patients?With?OralSquamous?Cell?Carcinoma. [pubmed:27889534] |
Pregnancy Hypertens | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study. [pubmed:28501283] |
Mol Nutr Food Res. | Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells. [pubmed:28181408] |
Archives of Gynecology and Obstetrics | Expression of annexin A2 in adenomyosis and dysmenorrhea [Pubmed: 31183557] |
Cancers | Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer [Pubmed: 31842290] |
PLASMA BIOMARKER FOR OVARIAN CANCER [] | |
Diagnostics | Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics 2021, 11, 69 [33406648] |
ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C [] |
Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins [] |
Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression [34376212] |